Table 5.
Association between total annual drug cost among prescribers and industry payments adjusted for gender, practice group size, years since graduation and region.
| Drug name1 | Mean annual cost of prescriptions by rheumatologists w/o payments, $ | Multiplier per $1000 consulting / compensation payments (95%CI)2 | Increase in Medicare spending per $1000 in consulting / compensation payments (95%CI), $2 | Multiplier per $100 food / beverage payments (95%CI)2 | Increase in Medicare spending per $100 in food / beverage payments, $2 |
|---|---|---|---|---|---|
| rACTH | 375,881 | 1.02 (1.01, 1.03) | 8,424 | 1.09 (1.05, 1.13) | 30,205 |
| Adalimumab | 151,219 | 1.01 (1.00, 1.02) | 1,580 | 1.06 (1.04, 1.08) | 8,231 |
| Etanercept | 171,088 | 1.02 (1.00, 1.04) | 3,679 | 1.11 (1.07, 1.15) | 17,728 |
| Infliximab | 367,952 | 1.14 (1.09, 1.20) | 52,084 | 1.20 (1.09, 1.33) | 72,421 |
| Golimumab | 53,316 | 1.05 (1.04, 1.06) | 2,847 | 1.23 (1.18, 1.28) | 9,805 |
| Rituximab | 204,643 | 1.03 (0.96, 1.11) | 6,189 | 1.10 (0.93, 1.29) | 18,223 |
| Certolizumab | 77,474 | 1.04 (0.98, 1.10) | 3,137 | 1.11 (1.03, 1.20) | 7,733 |
| Abatacept | 101,893 | 1.03 (1.00, 1.06) | 3,095 | 1.13 (1.07, 1.19) | 12,399 |
| Teriparatide | 39,544 | 1.11 (1.03, 1.19) | 4,172 | 1.29 (1.08, 1.55) | 11,237 |
| Denosumab | 36,733 | 1.14 (1.12, 1.16) | 5,156 | 1.44 (1.37, 1.52) | 13,443 |
1
There were no payments associated with hydroxychloroquine. Methotrexate and prednisone were excluded since more than 96% of the prescriptions were generic with no payment association.
2
Consulting and compensation = Speaker fees, consulting fees, honorariums, travel costs and grants; food and beverage=food and beverages, gifts, education, entertainment
rACTH, Repository corticotropin